Marick Laé

Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Year:

2026

High-grade serous-like carcinoma (HG-SL-Ca) of the breast is a newly recognized entity. We present the largest series with 34 cases. Inclusion criteria were breast carcinoma with ≥70% areas showing discordant well-formed tubules and high nuclear grade. Twenty-four (70.6%) were triple negative; 5 (14.7%) were ER+/HER2−; 2 (5.9%) were ER+/HER2+; and 3 (8.8%) were ER−/HER2+. Axillary lymph node metastasis was seen in 10 (31.3%) of 32 cases. Nine patients had neoadjuvant chemotherapy and 2 (22.2%) achieved pathologic complete response (pCR). Of the 32 patients with available follow-up data, 2 (6.3%) had local recurrence; 6 (18.8%) had distant metastasis; and 1 (3.1%) had both local recurrence and metastasis; 6 (18.8%) died of disease. Univariate analysis showed that only larger tumor size ( P =0.04) was associated with shorter metastasis-free survival; and larger tumor size ( P =0.003) and higher percentage of serous-like pattern ( P =0.03) were associated with worse overall survival. 27 (81.8%) of 33 cases had aberrant p53 expression; 16 (64.0%) of 25 showed p16 block positivity; 26 (86.7%) of 30 showed at least focal GATA-3 staining; 25 (89.3%) of 28 were negative for nuclear WT1 (3 had focal staining); and 28 (96.6%) of 29 were negative for PAX-8 (1 had focal staining). HG-SL-Ca of the breast has distinct morphology and the majority show aberrant p53 expression. Patients showed a low pCR rate and poor outcomes. The distinct morphology, immunohistochemistry (IHC) profile and clinical presentations warrant classifying these tumors as a new entity. The morphologic features and IHC studies can help differentiate breast HG-SL-Ca from other carcinomas.

Year:

2026

Aims Unusual morphologic patterns of breast carcinomas can raise diagnostic consideration for metastasis or special breast cancer subtypes with management implications. We describe rare invasive breast cancers that mimic serous carcinoma of the gynaecologic tract (serous‐like breast carcinomas, SLBC) and characterize their clinicopathologic, immunophenotypic, and genetic features. Methods and Results All patients were female ( n = 15, median age 49 years) without a history of gynaecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary and/or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple‐negative (TN, n = 10) or HER2‐positive ( n = 2) and grade 2 or 3, while some were oestrogen receptor (ER) low‐positive/HER2‐negative and low‐grade ( n = 3). CK5/6 was positive irrespective of grade or receptor status (10/10). All SLBC expressed GATA3 (14/15), TRPS1 (7/7), and/or mammaglobin (4/13). SOX10 was positive in most TN (9/10) and all ER low‐positive (3/3) cases, but negative in HER2‐positive tumours. WT1 was universally negative, and PAX8 was focal in one mammaglobin‐positive tumour. All ER‐negative SLBC were p53‐aberrant and 9/11 were p16‐aberrant, whereas ER‐positive tumours were wildtype for both markers (3/3). TP53 was the only frequently mutated gene, altered in all ER‐negative (10/10) but no ER‐positive (0/4) tumours. Clinical behaviour was variable. Only 1/6 patients achieved pathologic complete response to neoadjuvant chemotherapy. Conclusion SLBC is a rare morphologic pattern of invasive breast carcinoma that mimics metastatic serous gynaecologic carcinoma, a potential diagnostic pitfall. SLBC are heterogeneous with respect to grade, receptor profile, and oncogenic driver alterations, without specific genetic underpinnings identified. Additional studies are warranted to further evaluate the clinical behaviour of these tumours.

Year:

2025

Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We studied patient-level data from a pooled cohort across 12 institutions. Associations between RCB index, class, and EFS were assessed in ILC and non-ILC with mixed effect Cox models and multivariable analyses. Recursive partitioning was used in an exploratory model to stratify prognosis by RCB components. Of 5106 patients, the diagnosis was ILC in 216 and non-ILC in 4890. Increased RCB index was associated with worse EFS in both ILC and non-ILC ( p = 0.002 and p < 0.001, respectively) and remained prognostic when stratified by receptor subtype and adjusted for age, grade, T category, and nodal status. Recursive partitioning demonstrated residual invasive cancer cellularity as most prognostic in ILC. These results underscore the utility of RCB for evaluating NAC response in those with ILC.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Collaborators (7)

Fang Fan

City of Hope

UNITED STATES
View details

Sara Lopez-Tarruella

ASSOCIATE PROFESSOR

Universidad Complutense de Madrid

SPAIN
View details

Jean Abraham

Professor of Precision Breast Cancer Medicine

University of Cambridge

UNITED KINGDOM
View details

Yunn-Yi Chen

Professor

UCSF Medical Center

UNITED STATES
View details

Eliah Shamir

Chief Resident, Surgical Pathology Fellow

University of California, San Francisco

UNITED STATES
View details

Laura Esserman

University of California

UNITED STATES
View details

Rita A. Mukhtar

Professor of Surgery

University of California

UNITED STATES
View details